COMP <GO>
CABA vs SABS // EV/EBITDA & P/E VALUATION
Cabaletta Bio Inc. (NASDAQ) VS. SAB Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CABA 0
— SABS 4
■ METRIC PARITY
LAST: $1.59 (+4.28%) • MKT CAP: $268.7M
valuation
—
LAST: $3.23 (+0.94%) • MKT CAP: $293.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CABA VS. SABS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CABA | SABS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -27.40% | -7.60 | SABS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -15.55% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 7.07 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | SABS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.1 | 60.2 | -23.03 | SABS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 20.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $268.7M | $293.9M | -$25.2M | SABS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CABA REV | SABS REV | CABA GROSS % | SABS GROSS % | CABA FCF | SABS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$132.3M | -$45.7M |
| FY 2024 | $0 | $1.3M | — | — | -$90.4M | -$34.6M |
| FY 2023 | $0 | $2.2M | — | — | -$53.5M | -$25.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CABA // BETA —
SABS // BETA —